One of the main challenges is to selectively target cancer cells without inducing autoimmunity. Breaking tolerance can lead to immune-related adverse events (irAEs) where the immune system starts attacking healthy tissues. Another challenge is the heterogeneous nature of tumors. Different patients and even different parts of the same tumor can exhibit varying levels of immune tolerance, making it difficult to design one-size-fits-all treatments.
